KIT and gastrointestinal stromal tumor: Therefore, the implementation of ddPCR (or other sensitive) detection assays to identify resistant KIT mutations in plasma ctDNA is warranted for the development of more optimal treatment strategies in patients with GIST treated with TKIs.